Meridian Bioscience Expands Voluntary Recall of LeadCare Test Kits

Comments
Loading...
  • Meridian Bioscience Inc's VIVO subsidiary Magellan Diagnostics Inc has expanded the Class I recall of its LeadCare Test Kits used to detect lead in whole blood.
  • Magellan provides two controls in the test kits designed to mimic blood and are spiked with lead to specific target values with an associated acceptable range. 
  • Results of the control tests within the acceptable range indicate that the system is operating properly before testing patient samples. 
  • In May 2021, Magellan initiated this voluntary recall after identifying an ongoing issue with testing of the controls included in the LeadCare Test Kits. 
  • Magellan received reports that control tests of either the "Low-Control" and/or the "High-Control" generated a "low" result. 
  • Impacted LeadCare Test Kits lots could potentially underestimate blood lead levels when processing patient blood samples.
  • Related content: Benzinga's Full FDA Calendar.
  • Price Action: VIVO stock closed 1.73% higher at $20.59 on Wednesday.
Market News and Data brought to you by Benzinga APIs

Posted In:
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!